Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 19:14:151-161.
doi: 10.2147/IDR.S288877. eCollection 2021.

Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease

Tafere Mulaw Belete  1
Affiliations
Review

Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease

Tafere Mulaw Belete. Infect Drug Resist. .

Abstract

The global pandemic of COVID-19 caused by SARS-CoV-2 continues to spread and poses serious threats to public health and economic stability throughout the world. Thus, to protect the global population, developing safe and effective vaccines is mandatory to control the spread of SARS-CoV-2 pandemic. Since genomic sequences of SARS-CoV-2 and SARS-CoV-1 have similarity and use the same receptor (ACE2), it is important to learn from the development of SARS-CoV-1 vaccines for the development of SARS-CoV-2 vaccines. Normally vaccine development takes 10-15 years but vaccine development against SARS-CoV2 is going on at a very fast pace resulting in almost breakthrough methods of vaccine development by several research institutions. The whole process of vaccine development including clinical trials gets shortened and may be fast tracked to 15-18 months. Global collaborations and increased research efforts among the scientific community have led to more than 214 candidate vaccines globally. The current review highlights the different approaches and technologies used around the world for the design and development of the vaccines and also focuses on the recent status of the SARS-CoV-2 vaccine candidates under development by various institutions to combat the world threat of COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; clinical trials; spike protein; vaccine.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflicts of interest for this work.

Figures

Figure 1
Figure 1
Distribution of different SARS-CoV-2 vaccine candidate platform.
Figure 2
Figure 2
Life cycle of SARS-CoV-2 virus.
Figure 3
Figure 3
RNA vaccine platform.
See this image and copyright information in PMC

References

    1. Sharma A, Tiwari S, Deb MK, Marty JL. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): a global pandemic and treatments strategies. Int J Antimicrob Agents. 2020;10:106054. doi:10.1016/j.ijantimicag.2020.106054 - DOI - PMC - PubMed
    1. Wang N, Shang J, Jiang S, Du L. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;28(11):298. doi:10.3389/fmicb.2020.00298 - DOI - PMC - PubMed
    1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available from: https://covid19.who.int/. Accessed 15 December, 2020.
    1. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J Formosan Med Assoc. 2020;119(3):670. doi:10.1016/j.jfma.2020.02.009 - DOI - PMC - PubMed
    1. Samrat SK, Tharappel AM, Li Z, Li H. Prospect of SARS-CoV-2 spike protein: potential role in vaccine and therapeutic development. Virus Res. 2020;23:198141. doi:10.1016/j.virusres.2020.198141 - DOI - PMC - PubMed

LinkOut - more resources